Chemotherapy and Surgery in Stage IIIa Non-small Cell Lung Cancer  by Skarin, Arthur T.
LETTERS TO THE EDITOR
Multidisciplinary
Management of Lung
Cancer
To the Editor:
An interesting article by Leo et al.
on multidisciplinary management of
lung cancer and testing its efficacy was
published in the January 2007 issue of
The Journal.1 We also performed a sim-
ilar study.2,3 As mentioned by Leo et al.,
there is currently no information avail-
able in the literature regarding follow-up
of these patients after multidisciplinary
evaluation. Therefore, we are reporting
our results to compare our study with
theirs, although there is a time differ-
ence of 8 years between them. The lack
of such studies is also caused by the fact
that many journals seem reluctant to
publish articles that report the testing of
the efficacy of management in an insti-
tution and do not directly contribute new
knowledge on disease.
At the University Clinic of Respira-
tory and Allergic Diseases Golnik, Slov-
enia, the multidisciplinary management of
lung cancer has been going on since 1975,
although in Slovenia it is not established
by law. The multidisciplinary team is
composed of pulmonologists, a radiolo-
gist, a pathologist, a thoracic surgeon,
and a radiotherapist-oncologist. In 1996,
345 patients were diagnosed with pri-
mary lung cancer; 97% of diagnoses
were microscopically confirmed. The
patients were aged 37 to 90 years (mean,
65 years) with performance status
(Karnofsky) 80 for 49%, 60 to 80 for
38%, and60 for 13%. Clinical stage of
non-small cell lung cancer was stage
I for 22.5%, stage II for 11.5%, stage IIIA
for 17%, stage IIIB for 21%, stage IV
for 27%, and undeterminable for 1%.
Among patients with small cell lung
cancer, there was limited disease in 47%
and extended disease in 53% (Table 1).
Primary oncological therapy was
changed for 27 of 253 patients (11%),
most frequently for patients selected for
surgery. Of the 93 patients selected for
surgery, only 88 were admitted for tho-
racic surgery. Four patients refused the
intervention, whereas the remaining
seven patients were deemed unsuitable
for surgery by the surgeon.
The minimal follow-up time for
all patients was 5 years. The overall
crude median survival was 6.3 months.
The median survival among patients who
underwent resection was 33 months, 5.7
months among patients who underwent
irradiation, and 2.4 months for support-
ively treated patients. Twenty-seven pa-
tients (7.8%) survived for 5 years; all
but one underwent resection.
The diagnostic procedure from ad-
mittance to microscopic verification
took 7.4 days on average. The treatment
decision was made at the first multidis-
ciplinary discussion for all patients.
Leo et al.1 were surprised at the
1-year actuarial survival rate of 51.4%
among their patients. Considering the
mean follow-up time of only 152.6 
95.2 days, the calculated 365-day sur-
vival rate was, in our opinion, not sur-
prisingly high.
Lucˇka Debevec, MD, PhD and
Andrej Debeljak, MD, PhD
University Clinic of Respiratory and
Allergic Diseases Golnik, Slovenia
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Chemotherapy and
Surgery in Stage IIIa
Non-small Cell Lung
Cancer
To the Editor:
The recent comprehensive review
and meta-analysis of chemotherapy and
surgery versus surgery alone in stage III
non-small cell lung cancer (NSCLC) by
Burdett et al. in the September 2006
issue of The Journal points out the value
of initial chemotherapy before radical
surgery.1 This analysis of phase III stud-
ies supports our phase II study published
in 1989,2 which used initial preoperative
chemotherapy with the CAP (cyclo-
phosphamide, adriamycin, and cisplatin)
regimen in what we termed “marginally
or potentially resectable” NSCLC (later
called stage IIIA disease). As indicated
in the review, overall survival is key; in
our study, it was 30% at 5 years. This
figure has changed little over the past
two decades, primarily because of
deaths related to metastatic lung cancer.
What is needed is more effective sys-
temic therapy. New “targeted” treat-
ment, together with more active chemo-
therapy in a multimodality approach,
may improve the cure rate. This has
recently been termed “personalized ther-
apy.”3 In addition, better stratification of
stage IIIA subgroups based perhaps on
overall “bulk” disease may allow for
proper patient selection for multimodal-
ity therapy. The importance of restaging
before radical resection has been em-
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TABLE 1. Selected and Actual Primary
Treatment Modalities of Patients
Primary Treatment Selected Actual
Surgery 93 (28%) 77 (23%)
Radiotherapy 110 (32%) 102 (30%)
Chemotherapy 50 (15%) 47 (14%)
Supportive treatment 84 (25%) 111 (33%)
Total 337 (100%) 337 (100%)
Of the total 345 patients, 8 died before selection and
received no therapy. Table 1 reflects the treatment of the
remaining 337 patients.
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phasized by the important editorial in
the same issue of The Journal.4 Finally,
new prognostic information may allow
the identification of all surgical patients
with unfavorable lung cancer biology
(i.e., drug resistance and early micro-
scopic metastases not otherwise de-
tected by current staging procedures).
These include genomic studies,5,6 pro-
teomic assessment,7 and analysis of
DNA repair genes RRM1 and ERCC1.8
Arthur T. Skarin, MD, FACP,
FCCP†
Dana-Farber Cancer Institute, Harvard
Medical School, Boston, Massachusetts
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